{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-149895","form_type":"8-K","ticker":null,"cik":"0001845337","company_name":"Day One Biopharmaceuticals, Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.735816+00:00","generated_at":"2026-06-01T07:28:14.317700+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Day One sells Rare Pediatric Disease PRV for $108M; $8.1M to Viracta","bullets":["Closed sale of Priority Review Voucher for $108M in cash on May 29, 2024.","PRV awarded after FDA accelerated approval of OJEMDA (tovorafenib) on April 23, 2024.","$8.1M of proceeds will be paid to Viracta to fully satisfy PRV-related obligations.","Proceeds provide non-dilutive capital to fund OJEMDA launch and clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-149895","json":"https://secwatch.observer/filing/0001193125-24-149895.json","markdown":"https://secwatch.observer/filing/0001193125-24-149895.md","text":"https://secwatch.observer/filing/0001193125-24-149895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/0001193125-24-149895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/d834662d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:28:14.317700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ccdf7f62967053f9a067f91b11a31df4aad50ce","claim":"Day One Biopharmaceuticals, Inc. completed a disposition for $108.0 million (closed 2024-05-29).","evidence_excerpt":"pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for $108.0 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/0001193125-24-149895-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Consideration","value":"$108.0 million"},{"label":"Closing","value":"2024-05-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}